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138a Sunday, February 16, 2014hERG R56Q channels by i-eag domains could be translated into the environ-
ment of cardiac myocytes. hERG R56Q channels were expressed in hiPSC-
derived cardiomyocytes (hiPSC-CMs) and electrical properties of the cells
were measured with whole-cell patch-clamp. We found that, like in non-
myocyte cells, hERG R56Q had fast deactivation kinetics when expressed in
hiPSC-CMs. We report here that i-eag domains slowed the deactivation
kinetics in hERG R56Q currents in cardiomyocytes by making a direct associ-
ation with hERG R56Q channels, as measured with FRET spectroscopy, which
means that the modulatory role of i-eag domains function in the environment of
cardiomyocytes. Isolated eag domains rescued the dysfunction in hERG R56Q
channels in the cellular environment of a cardiomyocyte, which shows that they
may be useful as a biological therapeutic.
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Ether-a-go-go (EAG or KCNH1) potassium channels are inhibited by increases
of intracellular calcium concentration [Ca2þ]i through a calmodulin (CaM)
mediated mechanism. Three CaM binding sites have already been identified
on intracellular domains, one close to the N-terminally located eag-domain
and two close to the cyclic nucleotide binding homology domain (cNBHD)
on the C-terminus. Crystal structures of the cNBHD have revealed that instead
of binding cyclic nucleotides the binding pocket is occupied by a short b-strand
(intrinsic ligand). In this study we set out to elucidate the role of the cNBHD
and intrinsic ligand in CaM regulation of these channels. hEAG1 currents
were recorded in Xenopus oocytes using two electrode voltage clamp. Eleva-
tion of [Ca2þ]i by application of the Ca
2þ-ionophore ionomycin (5mM) and
SERCA inhibitor thapsigargin (5mM) profoundly inhibited wild-type (WT)
hEAG1 currents in a manner that was blocked by the CaM binding peptide mas-
toparan. Mutation of the intrinsic ligand slowed the time to 80% activation at
þ40 mV (t80%,act) from 256.35 5 31.05 ms (n=6) in WT hEAG1 to 1046 5
15.62 ms (n=3) in Y672A:L674A hEAG1. Substitution of binding pocket res-
idues with large residues also caused similar slowing of t80%,act (e.g. 682.65
17.9 ms for A609L, n=3). Despite this, none of these mutations caused a reduc-
tion in Ca2þ-sensitivity. However, deletion of the cNBHD abolished the
response to elevated [Ca2þ]i and also had a profound effect on channel gating
(t80%,act 426.6 5 44.67 ms, n=3). Overall, our results suggest that an intact
cNBHD is required for Ca2þ-dependent inhibition, but reducing the affinity
of the intrinsic ligand for its binding pocket is important for gating not Ca2þ-
sensitivity.
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Understanding the molecular basis of hERG (Kv11.1) inhibition is essential for
drug development. Here we systematically analyzed the mechanism and po-
tency of hERG inhibition by a library of 13 dofetilide derivatives1. Currents
through hERG channels stably expressed in HEK 293 cells were studied
applying whole-cell configuration using planar patch clamp technique2.
The estimated IC50s ranged between 4.350.7nM (LUF6200) and 297577nM
(LUF6139). An inverse relation was observed between potency (IC50) and rate
of block development. Analysis of the kinetics of block development revealed
that potency of dofetilide derivatives is predominantly determined by the drug
dissociation rate constant. In general, higher molecular weight led to higher
apparent drug affinity (r = 0.9).
LUF6200, the most active compound, has 2 nitro groups in para position of the
two aromatic rings and an ethyl moiety at the basic nitrogen atom. Pursuing a
Topliss approach at the phenoxy group further supports the positive contribu-
tion of the nitro group1, showing that substituents with electron withdrawing
groups in para position of the phenyl ring are beneficial for hERG blocking ac-
tivity. This points towards a pi-pi interaction of at least one of the aromatic
rings of dofetilide analogs with respective aromatic amino acids in the channel.
Docking of the set of compounds into a homology model of the hERG channelsupports this finding. A refined molecular model for dofetilide-hERG interac-
tion based on the novel functional data and mutational studies is proposed.
1. Shagufta et al. Exploring Chemical Substructures Essential for hERG Kþ
Channel Blockade by Synthesis and Biological Evaluation of Dofetilide Ana-
logues. ChemMedChem 4, 1722-1732 (2009).
2. Farre, C. & Fertig, N. HTS techniques for patch clamp-based ion channel
screening - advances and economy. Expert Opin. Drug Discov. 7, 515-524
(2012).
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hERG Kþ channels are sensitive to pharmacological inhibition by many
different drugs including Class I and Class III antiarrhythmics. These drugs
exhibit differences regarding the reliance of hERG current (IhERG) blockade
on channel inactivation: Class Ia (quinidine and disopyramide) and Ic (propa-
fenone) agents are less dependent on inactivation than are Class III methanesul-
phonanilide compounds (dofetilide and E-4031) (1-3). Flecainide is a Class Ic
agent that inhibits IhERG at clinically relevant concentrations (4) and its sensi-
tivity to hERG inactivation has not been systematically investigated. This study
was undertaken to evaluate the influence of inactivation on flecainide blockade
of hERG, through the use of attenuated-inactivation mutants S631A, N588K
and S631A/N588K (3). IhERG was recorded using whole-cell patch-clamp
at 37oC from hERG-expressing HEK293 cells. IhERG tails were measured
at 40mV after a 2sec depolarizing step from 80mV to þ20mV (nR5 at
each concentration). Flecainide produced a concentration-dependent inhibition
of wild-type (WT) IhERG with an IC50 of 1.49mM (CI:1.27-1.74). The IC50
for inhibition of S631A-IhERG [7.49mM (CI:6.33-8.87)] was ~5-fold that for
WT-IhERG, whilst that for N588K-IhERG [6.50mM (CI:5.37-7.88)] was
~4.4-fold that of WT-IhERG. The S631A/N588K double mutant, which leads
to a greater attenuation of IhERG inactivation than does either individual mu-
tation (3), exhibited an IC50 [19.16mM (CI:15.43-23.80)] ~12.9 fold that of
WT-IhERG. Comparison of these data with prior work using these
inactivation-mutants (3) is suggestive that flecainide inhibition of IhERG de-
pends on inactivation to a slightly greater extent than Class Ia drugs and the
Class Ic drug propafenone, but to a much lesser extent than does E-4031.
Funded by the British Heart Foundation.
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2. Perrin et al. Mol Pharmacol 2008; 74:1443-52.
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Block of hERG1 Kþ channels by many drugs delays cardiac repolarization,
prolongs QT interval and is associated with an increased risk of cardiac
arrhythmia. A common finding is that high affinity binding of potent hERG
channel blockers is inactivation state dependent. The most compelling evi-
dence for this assertion is that point mutations in hERG that inhibit or elimi-
nate inactivation gating (e.g., S620T or G628C/S631C) can reduce drug
affinity by >100-fold. Here we examine the link between hERG1 inactivation
and blocker affinity in more detail by characterization of concatenated tetra-
mers containing a variable number of subunits harboring mutations that disrupt
inactivation. For concatenated tetramers containing only wild-type hERG sub-
units (wt4) the IC50’s were 0.20 mM, 0.16 mM, 0.18 mM for cisapride, MK499
and dofetilide, respectively. The presence of a single S620T subunit in a
tetramer (ST1/wt3) disrupted inactivation gating (þ76 mV shift in V0.5) similar
to a homomeric S620T tetramer (ST4; þ87 mV shift in V0.5). For ST4 chan-
nels, IC50’s were 10.6 mM, 6.97 mM, 14.1 mM for cisapride, MK499 and do-
fetilide, respectively. In contrast, for ST1/wt3 channels the IC50’s were 0.60
mM, 1.51 mM, 3.16 mM for the same three drugs. Thus, despite similar effects
on inactivation, drug sensitivity of ST4 channels was significantly less than
ST1/wt3 channels, indicating that the S620T mutation alters drug binding by
a mechanism other than attenuation of inactivation. Unlike S620T, the double
mutation G628C/S631C completely eliminates inactivation and concatenated
tetramers containing either one or four G628C/S631C subunits induced the
same 2.5-fold decrease of cisapride sensitivity (IC50: 0.50 mM and 0.47
mM). Together these findings indicate that preferential binding of drugs to
the inactivated state of hERG channels is far less important than is commonly
claimed.
